With a Steady CAGR of 8.68%, Global SGLT2 Inhibitors Market to Reach USD30.34 Billion by 2030

• Overview
• Table of Content
• Research Methodology
• Download Free Sample

The Global SGLT2 Inhibitors Market size was valued at around USD18.41 billion in 2024 and is projected to reach USD30.34 billion by 2030. Along with this, the market is estimated to grow at a CAGR of around 8.68% during the forecast period, i.e., 2025-30, cites MarkNtel Advisors in the recent research report. The market growth is driven by various factors, including the high prevalence of chronic disorders, including type-2 diabetes, chronic kidney disorders, cardiovascular diseases, etc., the support from governments of different countries by announcing and conducting mass screening programs and initiatives for effectively detecting and managing these chronic disorders, and the adoption of the next-generation SGLT2 Inhibiting drugs. One of the major growth factors is the continuously rising elderly population worldwide, which is a highly vulnerable population for such diseases, and has increased the demand for advanced medications to control these types of chronic diseases, including SGLT2 inhibitors.  

Additionally, governments of different countries, like India, Indonesia, China, Ireland, the US, Canada, etc., are significantly supporting the market growth by heavily investing in the mass detection and screening initiatives for early detection and better cure of particular chronic diseases, such as type 2 diabetes. Also, a substantial amount for research and development, along with intensive & successful clinical trials in the field of pharmaceuticals, including SGLT2 inhibitors, are contributing to the potential growth of the global SGLT2 inhibitor industry. Moreover, the rapid adoption of the next-generation SGLT2 inhibitors like Brenzavvy, Inpefa, etc., is gaining momentum and actively transforming this market, as these are with enhanced efficiency and better treatment options over traditional ones.

However, the high retail prices of these drugs are putting a financial barrier to many individuals, especially those in rural areas with constrained budgets. In addition, most people and health experts are still unaware of these kinds of drugs, which are further hampering the market growth, further states the research report, “Global SGLT2 Inhibitors Market Analysis, 2025.”

Global SGLT2 Inhibitors Market Segmentation Analysis

Jardiance is the Most Preferred Drug Type

Based on the drug type, the market is further classified into Jardiance (empagliflozin), Farxiga (dapagliflozin), Invokana (canagliflozin), Inpefa (sotagliflozin), Qtern (dapagliflozin/saxagliptin), and others. Among these, the Jardiance (empagliflozin) holds the largest market share of about 32%. The dominance is due to the high clinical performance of this drug over other kinds of drugs, proven by the large-scale clinical trials such as the EMPA-REG, DAPA-HF, and CREDENCE.

For instance, the Eli Lilly company, with others, has conducted a study including almost 7,000 patients suffering from type 2 diabetes with a high risk of cardiovascular diseases. This study showed that if a patient is using Jardiance, then the chances of a longer stay in hospitals and death are significantly minimized. On a similar pattern, all the other trials show the supremacy and high level effectiveness of this specific type of drug as compared to other types of drugs. Therefore, a large group of patients is using this drug, which is ultimately augmenting the market share of Jardiance (empagliflozin) in the global market for SGLT2 Inhibitors. Moreover, Jardiance has been approved in more than 100 countries, which shows its widespread adoption around the globe, hence generating maximum revenue for the market.

North America Leads the SGLT2 Inhibitors Industry

North America is leading the Global SGLT2 Inhibitors Market, with a market share of more than 42%. People in North America are generating significant market demand because of the rising number of patients, especially the elderly population in the countries of this region. As the elderly population is highly vulnerable to chronic diseases, they prefer SGLT2 Inhibitors. According to the US Census (2024), around 58 million people are aged above 65 years, which is roughly about 18% of the entire national population. Out of this elderly group, over 45 million senior citizens were diagnosed with chronic diseases in the United States. Therefore, this high number of aged individuals and the high number of aged people suffering from chronic diseases is leading to increased demand for SGLT2 Inhibitors, which is ultimately augmenting the size & volume of the regional SGLT2 Inhibitors Industry.

Moreover, other North American countries like Canada and Mexico also have a high proportion of aged people, and a large number of individuals have been identified with one or more types of chronic disease; thus, in these countries also, there is an increasing demand for SGLT2 Inhibitors.

Competitive Landscape

With strategic initiatives, such as mergers, collaborations, and acquisitions, the leading market companies, including Astellas, AstraZeneca, Boehringer Ingelheim International, Bristol-Myers Squibb Company, Eli Lilly and Company, Glenmark Pharmaceuticals, Johnson & Johnson (Janssen Pharmaceuticals), Lexicon Pharmaceuticals, Lupin Limited, Merck, Sanofi, TheracosBio, and Others are looking forward to strengthening their market positions.

Key Questions Answered in the Research Report

1. What are the industry’s overall statistics or estimates (Overview, Size- By Value, Forecast Numbers, Segmentation, Shares)?
2. What are the trends influencing the current scenario of the market?
3. What key factors would propel and impede the industry across the globe?
4. How has the industry been evolving in terms of geography & solution adoption?
5. How has the competition been shaping up across various regions?
6. How have buying behavior, customer inclination, and expectations from solution providers been evolving during 2020-30?
7. Who are the key competitors, and what strategic partnerships or ventures are they coming up with to stay afloat during the projected time frame?